Form S-3 Xeris Biopharma Holdings
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Xeris Pharmaceuticals Inc. (XERS) Files $250M Mixed Shelf
March 6, 2025 5:00 PM ESTXeris Pharmaceuticals Inc. (NASDAQ: XERS) has filed $250,000,000 mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
